Key result
Balloon pulmonary angioplasty demonstrates beneficial clinical effects with acceptable risks and is recommended for nonoperable chronic thromboembolic pulmonary hypertension.
Why the study?
Although pulmonary endarterectomy is the treatment of choice for CTEPH, some patients are inoperable, and the role and long-term outcomes of evolving balloon pulmonary angioplasty require clarification.
Balloon pulmonary angioplasty is an effective and increasingly recommended interventional treatment for patients with inoperable chronic thromboembolic pulmonary hypertension.
Patients with chronic thromboembolic pulmonary hypertension (CTEPH), characterized by pulmonary artery obstruction with unresolved embolism, have poor prognosis. Although pulmonary endarterectomy is the treatment of choice in the management of CTEPH, some patients are not operable. Balloon pulmonary angioplasty (BPA) is a catheter-based interventional treatment for patients with CTEPH. BPA has been considered a high-risk procedure, although the beneficial effects were promising. BPA has been modified and refined over the last 10 years. Recent evidence about modern BPA has consistently demonstrated the beneficial clinical effects with acceptable risks. BPA is now recommended in nonoperable CTEPH patients in addition to targeted medical therapy, although several questions such as long-term prognosis remain unanswered. BPA is still evolving for its application in the CTEPH treatment strategy. Further investigations are still necessary to define the role of BPA.
No takes yet. Share an insight, caveat, or question.
Takeshi Ogo (2020) conducted a review in Chronic thromboembolic pulmonary hypertension (CTEPH). Balloon pulmonary angioplasty (BPA) was evaluated. Balloon pulmonary angioplasty demonstrates beneficial clinical effects with acceptable risks and is recommended for nonoperable chronic thromboembolic pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: